{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:10:47Z","timestamp":1786997447727,"version":"build-2736575974"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.thromres.2022.08.003","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T22:53:35Z","timestamp":1659740015000},"page":"8-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Splanchnic vein thrombosis associated with myeloproliferative neoplasms"],"prefix":"10.1016","volume":"218","author":[{"given":"Douglas","family":"Tremblay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Winters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan D.","family":"Beckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Naymagon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D.","family":"Schiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.thromres.2022.08.003_bb0005","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/MBC.0000000000000901","article-title":"The utility of thrombophilia testing in patients with newly diagnosed portal vein thrombosis","volume":"31","author":"Tremblay","year":"2020","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"1","key":"10.1016\/j.thromres.2022.08.003_bb0010","first-page":"99","article-title":"Antithrombotic treatment of splanchnic vein thrombosis: results of an international registry","volume":"40","author":"Ageno","year":"2014","journal-title":"Semin. Thromb. Hemost."},{"issue":"20","key":"10.1016\/j.thromres.2022.08.003_bb0015","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.thromres.2022.08.003_bb0020","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"issue":"7037","key":"10.1016\/j.thromres.2022.08.003_bb0025","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.thromres.2022.08.003_bb0030","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer J."},{"issue":"2","key":"10.1016\/j.thromres.2022.08.003_bb0035","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.hoc.2020.12.001","article-title":"Overview of myeloproliferative neoplasms: history, pathogenesis, diagnostic criteria, and complications","volume":"35","author":"Tremblay","year":"2021","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"5","key":"10.1016\/j.thromres.2022.08.003_bb0040","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study","volume":"168","author":"Hultcrantz","year":"2018","journal-title":"Ann. Intern. Med."},{"issue":"13","key":"10.1016\/j.thromres.2022.08.003_bb0045","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.3748\/wjg.v12.i13.2115","article-title":"Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies","volume":"12","author":"Ogren","year":"2006","journal-title":"World J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.thromres.2022.08.003_bb0050","doi-asserted-by":"crossref","first-page":"167","DOI":"10.7326\/0003-4819-151-3-200908040-00004","article-title":"Etiology, management, and outcome of the Budd-Chiari syndrome","volume":"151","author":"Darwish Murad","year":"2009","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.thromres.2022.08.003_bb0055","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/ejh.13335","article-title":"Outcomes of splanchnic vein thrombosis in patients with myeloproliferative neoplasms in a single center experience","volume":"104","author":"Tremblay","year":"2020","journal-title":"Eur. J. Haematol."},{"issue":"9","key":"10.1016\/j.thromres.2022.08.003_bb0060","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.3109\/10428194.2012.759656","article-title":"Age-related differences in disease characteristics and clinical outcomes in polycythemia vera","volume":"54","author":"Stein","year":"2013","journal-title":"Leukemia & lymphoma"},{"issue":"4","key":"10.1016\/j.thromres.2022.08.003_bb0065","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/bjh.13080","article-title":"A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera","volume":"167","author":"Lussana","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2022.08.003_bb0070","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/874146","article-title":"Gender and vascular complications in the JAK2 V617F-positive myeloproliferative neoplasms","volume":"2011","author":"Stein","year":"2011","journal-title":"Thrombosis"},{"issue":"3","key":"10.1016\/j.thromres.2022.08.003_bb0075","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1160\/TH07-09-0570","article-title":"Venous thrombosis in oral contraceptive users and the presence of the JAK2 V617F mutation","volume":"99","author":"Grandone","year":"2008","journal-title":"Thromb. Haemost."},{"issue":"8102","key":"10.1016\/j.thromres.2022.08.003_bb0080","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0140-6736(78)92098-6","article-title":"Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia","volume":"2","author":"Pearson","year":"1978","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.thromres.2022.08.003_bb0085","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/blood-2008-11-191544","article-title":"The presence of JAK2V617F mutation in the liver endothelial cells of patients with budd-chiari syndrome","volume":"113","author":"Sozer","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.thromres.2022.08.003_bb0090","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2012-01-404889","article-title":"Spleen endothelial cells from patients with myelofibrosis harbor the JAK2 V617F mutation","volume":"121","author":"Rosti","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.thromres.2022.08.003_bb0095","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/bjh.14327","article-title":"Granulocyte whole exome sequencing and endothelial JAK2V617F in patients with JAK2V617F positive Budd-Chiari syndrome without myeloproliferative neoplasm","volume":"180","author":"Helman","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.thromres.2022.08.003_bb0100","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1055\/s-0038-1667015","article-title":"Endothelial cells harbouring the JAK2V617F mutation display pro-adherent and pro-thrombotic features","volume":"118","author":"Guadall","year":"2018","journal-title":"Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2022.08.003_bb0105","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3324\/haematol.2018.195321","article-title":"Vascular endothelial cell expression of JAK2(V617F) is sufficient to promote a pro-thrombotic state due to increased P-selectin expression","volume":"104","author":"Guy","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2022.08.003_bb0110","unstructured":"M. Castiglione, Y.-P. Jiang, C. Mazzeo, S. Lee, J.-S. Chen, K. Kaushansky, W. Yin, R.Z. Lin, H. Zheng, H. Zhan, Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm, Journal of Thrombosis and Haemostasis n\/a(n\/a)."},{"issue":"1","key":"10.1016\/j.thromres.2022.08.003_bb0115","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1182\/blood-2015-12-684688","article-title":"Patterns of expression of factor VIII and von willebrand factor by endothelial cell subsets in vivo","volume":"128","author":"Pan","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.thromres.2022.08.003_bb0120","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1111\/jth.15095","article-title":"Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm","volume":"18","author":"Castiglione","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.thromres.2022.08.003_bb0125","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000123","article-title":"Von willebrand and factor VIII portosystemic circulation gradient in cirrhosis: implications for portal vein thrombosis","volume":"11","author":"Praktiknjo","year":"2020","journal-title":"Clin. Transl. Gastroenterol."},{"issue":"2 Pt 2","key":"10.1016\/j.thromres.2022.08.003_bb0130","first-page":"H740","article-title":"Regulation of P-selectin expression in human endothelial cells by nitric oxide","volume":"273","author":"Armstead","year":"1997","journal-title":"Am. J. Phys."},{"issue":"5","key":"10.1016\/j.thromres.2022.08.003_bb0135","doi-asserted-by":"crossref","DOI":"10.1172\/JCI124566","article-title":"Erythrocyte-derived microvesicles induce arterial spasms in JAK2V617F myeloproliferative neoplasm","volume":"130","author":"Poisson","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.thromres.2022.08.003_bb0140","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3109\/10715762.2013.860225","article-title":"Nitric oxide scavenging by cell-free hemoglobin may be a primary factor determining hypertension in polycythemic patients","volume":"48","author":"Rusak","year":"2014","journal-title":"Free Radic. Res."},{"issue":"39","key":"10.1016\/j.thromres.2022.08.003_bb0145","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1038\/onc.2017.148","article-title":"STAT3 activation in endothelial cells is important for tumor metastasis via increased cell adhesion molecule expression","volume":"36","author":"Kim","year":"2017","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.thromres.2022.08.003_bb0150","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.049029","article-title":"Suppressing STAT3 activity protects the endothelial barrier from VEGF-mediated vascular permeability","volume":"14","author":"Wang","year":"2021","journal-title":"Dis. Model. Mech."},{"issue":"5","key":"10.1016\/j.thromres.2022.08.003_bb0155","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/MBC.0000000000000088","article-title":"Selected parameters of hemostasis in patients with myeloproliferative neoplasms","volume":"25","author":"Gadomska","year":"2014","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"1","key":"10.1016\/j.thromres.2022.08.003_bb0160","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1034\/j.1600-0609.2002.01732.x","article-title":"Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera","volume":"69","author":"Jensen","year":"2002","journal-title":"Eur. J. Haematol."},{"issue":"5","key":"10.1016\/j.thromres.2022.08.003_bb0165","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2022.08.003_bb0170","series-title":"Current Hematologic Malignancy Reports","article-title":"Novel pathophysiological mechanisms of thrombosis in myeloproliferative neoplasms","author":"Reeves","year":"2021"},{"key":"10.1016\/j.thromres.2022.08.003_bb0175","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.thromres.2017.06.030","article-title":"Clinical manifestations and imaging tools in the diagnosis of splanchnic and cerebral vein thromboses","volume":"163","author":"Riva","year":"2018","journal-title":"Thromb. Res."},{"issue":"5","key":"10.1016\/j.thromres.2022.08.003_bb0180","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/1358863X10379673","article-title":"Mesenteric venous thrombosis","volume":"15","author":"Harnik","year":"2010","journal-title":"Vasc. Med."},{"issue":"3","key":"10.1016\/j.thromres.2022.08.003_bb0185","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1148\/radiographics.22.3.g02ma10527","article-title":"Mesenteric venous thrombosis: diagnosis and noninvasive imaging","volume":"22","author":"Bradbury","year":"2002","journal-title":"Radiographics"},{"issue":"25","key":"10.1016\/j.thromres.2022.08.003_bb0190","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1182\/blood-2011-09-376517","article-title":"Myeloproliferative neoplasms in budd-chiari syndrome and portal vein thrombosis: a meta-analysis","volume":"120","author":"Smalberg","year":"2012","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.thromres.2022.08.003_bb0195","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1182\/blood.V128.22.3121.3121","article-title":"Distinct clinical, laboratory, and molecular features of myeloproliferative neoplasm patients presenting with splanchnic vein thrombosis","volume":"128","author":"How","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2022.08.003_bb0200","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.thromres.2018.05.007","article-title":"Prevalence of CALR mutations in splanchnic vein thrombosis: a systematic review and meta-analysis","volume":"167","author":"Li","year":"2018","journal-title":"Thromb. Res."},{"issue":"25","key":"10.1016\/j.thromres.2022.08.003_bb0205","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.thromres.2022.08.003_bb0210","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jhep.2017.04.021","article-title":"Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: a prospective cohort study","volume":"67","author":"Poisson","year":"2017","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.thromres.2022.08.003_bb0215","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jhep.2020.06.045","article-title":"Next generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis","volume":"74","author":"Magaz","year":"2021","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.thromres.2022.08.003_bb0220","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/hep.21435","article-title":"Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis","volume":"44","author":"Primignani","year":"2006","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.thromres.2022.08.003_bb0225","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1182\/blood-2007-11-125328","article-title":"The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases","volume":"111","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.thromres.2022.08.003_bb0230","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.leukres.2015.03.009","article-title":"Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis","volume":"39","author":"Gianelli","year":"2015","journal-title":"Leuk. Res."},{"key":"10.1016\/j.thromres.2022.08.003_bb0235","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.thromres.2020.11.027","article-title":"Prevalence of definite antiphospholipid syndrome in carriers of the JAK2(V617F) mutation","volume":"198","author":"Janjetovic","year":"2021","journal-title":"Thromb. Res."},{"issue":"11","key":"10.1016\/j.thromres.2022.08.003_bb0240","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1111\/j.1538-7836.2011.04484.x","article-title":"Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms","volume":"9","author":"Hoekstra","year":"2011","journal-title":"J. Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2022.08.003_bb0245","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00277-020-03965-z","article-title":"Groups, natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis","volume":"99","author":"Alvarez-Larran","year":"2020","journal-title":"Ann. Hematol."},{"issue":"3","key":"10.1016\/j.thromres.2022.08.003_bb0250","doi-asserted-by":"crossref","first-page":"E61","DOI":"10.1002\/ajh.24993","article-title":"Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: the Mayo clinic experience with 84 consecutive cases","volume":"93","author":"Lavu","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"15","key":"10.1016\/j.thromres.2022.08.003_bb0255","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1182\/bloodadvances.2020002414","article-title":"Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses","volume":"4","author":"Debureaux","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.thromres.2022.08.003_bb0260","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.103","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients","volume":"6","author":"De Stefano","year":"2016","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.thromres.2022.08.003_bb0265","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.trsl.2020.04.012","article-title":"Venous thrombosis of the liver: current and emerging concepts in management","volume":"225","author":"Naymagon","year":"2020","journal-title":"Transl. Res."},{"issue":"12","key":"10.1016\/j.thromres.2022.08.003_bb0270","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.cgh.2008.07.031","article-title":"Portal hypertension-related complications after acute portal vein thrombosis: impact of early anticoagulation","volume":"6","author":"Turnes","year":"2008","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.thromres.2022.08.003_bb0275","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s11239-020-02052-4","article-title":"Portal vein thrombosis patients harboring JAK2V617F have poor long-term outcomes despite anticoagulation","volume":"50","author":"Naymagon","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"issue":"1","key":"10.1016\/j.thromres.2022.08.003_bb0280","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/hep.31646","article-title":"Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases","volume":"73","author":"Northup","year":"2021","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.thromres.2022.08.003_bb0285","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11239-015-1308-1","article-title":"Guidance for the management of venous thrombosis in unusual sites","volume":"41","author":"Ageno","year":"2016","journal-title":"J. Thromb. Thrombolysis"},{"issue":"4","key":"10.1016\/j.thromres.2022.08.003_bb0290","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/bloodadvances.2019001310","article-title":"The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis","volume":"4","author":"Naymagon","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2022.08.003_bb0295","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.vph.2018.05.002","article-title":"Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis","volume":"113","author":"Hanafy","year":"2019","journal-title":"Vasc. Pharmacol."},{"issue":"1","key":"10.1016\/j.thromres.2022.08.003_bb0300","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.mayocp.2017.10.007","article-title":"Rivaroxaban and apixaban for initial treatment of acute venous thromboembolism of atypical location","volume":"93","author":"Janczak","year":"2018","journal-title":"Mayo Clin. Proc."},{"issue":"10","key":"10.1016\/j.thromres.2022.08.003_bb0305","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1038\/s41375-021-01279-1","article-title":"Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients","volume":"35","author":"Barbui","year":"2021","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.thromres.2022.08.003_bb0310","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/jth.14836","article-title":"Anticoagulant therapy for splanchnic vein thrombosis: ISTH SSC subcommittee control of anticoagulation","volume":"18","author":"Di Nisio","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"10","key":"10.1016\/j.thromres.2022.08.003_bb0315","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi-Ros","year":"2019","journal-title":"Ann. Intern. Med."},{"issue":"13","key":"10.1016\/j.thromres.2022.08.003_bb0320","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.thromres.2022.08.003_bb0325","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1002\/hep.26306","article-title":"Good long-term outcome of Budd-Chiari syndrome with a step-wise management","volume":"57","author":"Seijo","year":"2013","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.thromres.2022.08.003_bb0330","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1002\/hep.31915","article-title":"TIPS for adults without cirrhosis with chronic mesenteric venous thrombosis and EHPVO refractory to standard-of-care therapy","volume":"74","author":"Knight","year":"2021","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.thromres.2022.08.003_bb0335","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1007\/s00270-014-0989-8","article-title":"Percutaneous mesocaval shunt creation in a patient with chronic portal and superior mesenteric vein thrombosis","volume":"38","author":"Bercu","year":"2015","journal-title":"Cardiovasc. Intervent. Radiol."},{"issue":"3","key":"10.1016\/j.thromres.2022.08.003_bb0340","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1053\/j.gastro.2008.05.051","article-title":"G. Budd-Chiari Syndrome-Transjugular Intrahepatic Portosystemic Shunt, TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients","volume":"135","author":"Garcia-Pagan","year":"2008","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.thromres.2022.08.003_bb0345","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/lt.21282","article-title":"Eighteen years of liver transplantation experience in patients with advanced budd-chiari syndrome","volume":"14","author":"Ulrich","year":"2008","journal-title":"Liver Transpl."},{"issue":"6","key":"10.1016\/j.thromres.2022.08.003_bb0350","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1097\/SLA.0b013e31825429c0","article-title":"Multivisceral transplantation for diffuse portomesenteric thrombosis","volume":"255","author":"Vianna","year":"2012","journal-title":"Ann. Surg."},{"issue":"21","key":"10.1016\/j.thromres.2022.08.003_bb0355","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1182\/bloodadvances.2020002727","article-title":"Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase","volume":"4","author":"Gupta","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.thromres.2022.08.003_bb0360","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/ajt.16324","article-title":"Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: a consensus expert opinion statement","volume":"21","author":"Al-Adra","year":"2021","journal-title":"Am. J. Transplant."},{"issue":"5","key":"10.1016\/j.thromres.2022.08.003_bb0365","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from european LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.thromres.2022.08.003_bb0370","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41408-018-0151-y","article-title":"Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases","volume":"8","author":"Stefano","year":"2018","journal-title":"Blood Cancer J."},{"issue":"2","key":"10.1016\/j.thromres.2022.08.003_bb0375","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ajh.24614","article-title":"Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms","volume":"92","author":"Pieri","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"12","key":"10.1016\/j.thromres.2022.08.003_bb0380","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1038\/s41375-019-0524-7","article-title":"A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis","volume":"33","author":"Mascarenhas","year":"2019","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.thromres.2022.08.003_bb0385","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.bbmt.2012.04.011","article-title":"Incidence and risk factors for early hepatotoxicity and its impact on survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation","volume":"18","author":"Wong","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"15","key":"10.1016\/j.thromres.2022.08.003_bb0390","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.thromres.2022.08.003_bb0395","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004938482200336X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004938482200336X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:48:59Z","timestamp":1758736139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004938482200336X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":79,"alternative-id":["S004938482200336X"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2022.08.003","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Splanchnic vein thrombosis associated with myeloproliferative neoplasms","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2022.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}